phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Continuous glucose monitor (CGM) system chiefly consists of three major components, namely sensors, transmitters & receivers and Insulin Pumps. However, in conventional CGM systems, insulin pumps were optional, whereas they are an integral part of modern CGMs. CGMs are more expensive than the conventional glucose monitoring systems. Technological innovation such as launch of artificial pancreas has taken diabetic care management to a next level and they are further putting efforts in advancing closed loop algorithms. Thus, advancement in CGM systems makes possible early detection of hypoglycemia in an easy manner in comparison to infrequent point-of-care glucose meter measurements. However, there are few limitations associated with the CGMs, as they do not replace finger prick method for accurate readings, they require skill and training in diabetes management and they are not yet covered by majority of the insurance providers.

Currently CGMs are chiefly used in home settings, diagnosed centers and hospitals. Main use of CGMs are for continuously monitoring the glucose level irrespective of the location and its usage is almost hassle free and hence is comfortably used in home settings. Diagnostics center is another application area which is also gaining popularity due to increase in use in case studies so as to allow effective reporting methods of glucose levels. Currently, adoption of CGMs in the hospitals settings currently is not overwhelming however it is expected to gain a boost in next three to four years as it offers benefits in ICU medication such as:

  • Detection of hypo-hyperglycemia
  • Prediction of future glucose levels
  • Instant feedback regarding treatment
  • Improved patient comfort
  • Assistance with insulin dose 
  • Less time

In the past, blood glucose meters were used in diagnostic centers/clinics for blood glucose monitoring, which simply displayed the glucose level. However, continuous glucose monitors replaced meters to a significant extent, as they are convenient and less painful to use. CGM provides patients with glucose trend graphs, alerts on highs or lows in glucose levels (anytime as customized), and insights into how food and activity patterns impact diabetes. Many diagnostic centers set up a professional CGM program. In this program, the device records glucose measurements after a predetermined period of time throughout the day and send alerts through alarm signals. All the readings and measurements are mostly downloaded onto a computer for analysis. Some devices have the ability to record events related to diet, exercise and insulin doses, which enables patients to understand the effectiveness of their diabetes management program. This stored data allow medical practitioners to understand patients’ efforts towards managing diabetes and where they need to improve. However, the main concern with CGM is accuracy.

North America CGM Market In Diagnostic centers 2011-2020

The CGM systems need to be calibrated with a finger-stick (twice or thrice a day) to ensure improved accuracy. Patients thus require finger-sticks for calibration, and it is also recommended to use finger-stick measurements for checking hypoglycemia or hyperglycemia before taking corrective action.

In order to manage diabetes effectively real-time continuous glucose monitoring (CGM) is of utmost importance in all age group. CGM enables effective managing blood glucose level by providing trend data as well as alarms if the glucose level falls low or high. Revenue generated due to adoption of CGMs among middle elderly group is expected to account for the largest share in 2020. Youth market will have the highest growth rate at 15.9% during the analysis period.

Incidences of diabetes in children are increasing every year. Europe has highest prevalence of diabetes with type-1 diabetes around 129,000 with 20,000 new cases per year. Approximately half of the patients diagnosed with type-1 diabetes are children every year. Countries such as the U.K., the Russian Federation and France have highest number of Type-1 diabetic children patients.

In low income regions such as Africa and some of the Asian countries children diagnosed with type-1 diabetes often goes undiagnosed. Even if they are diagnosed in time they lack means to obtain insulin, syringes and monitoring devices and as a result they die. This is the main reason why we get to see lesser number of children patients with diabetes in such regions.

Continuous Glucose Monitoring Market brings good news for medical device manufacturers.

KEY BENEFITS

  • The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more
  • Market is forecast for the period 2013 - 2020 with market revenues for 2 historic years of 2010 and 2012
  • Identification and analysis of key pockets of investment for CGM manufacturers
  • Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
  • Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario
  • The report identifies and profiles key market participants that would drive innovation in the CGM market

KEY MARKET SEGMENTS

GLOBAL MARKET, BY DEVICES

  • Transmitter and Receivers
  • Sensors
  • Insulin Pump

GLOBAL MARKET, BY APPLICATION

  • Diagnostics/Clinics
  • Hospitals
  • Home Settings

GLOBAL MARKET, BY AGE

  • Children and Teens
  • Youth
  • Middle, Elderly and Aged

GLOBAL MARKET, BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • Row

KEY AUDIENCES

  • Medical Devices Manufacturers
  • Research Institutions
  • Healthcare Institutions
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW

3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market

3.2.1 Type-1 Diabetes

3.2.1.1 Type-1 Diabetes in Young People

3.2.2 Type-2 Diabetes

3.2.2.1 Type-2 Diabetes in Young People

3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes

3.3 Market Intelligence

3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020

3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies

3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market

3.3.3.1 Continuous Glucose Monitors Market – by Device
3.3.3.2 Continuous Glucose Monitors Market – by Applications
3.3.3.3 Continuous Glucose Monitors Market – by Geography

3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics

3.6.1 Drivers

3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies

3.6.2 Restraints

3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.6.3 Market Opportunity

3.6.3.1 Growth in Emerging Market

3.6.4 Winning Strategies for Mncs in Emerging Markets

3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5  Adopting An Emerging-Market Attitude

Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES

4.1 Transmitter and Receivers
4.2 Sensors

4.2.1 Market Trend

4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology – Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology – Real-Time Sensors

4.3 Insulin Pump

4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend

Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION

5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice

5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed

Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET – BY AGE

6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged

Chapter: 7 CGM SYSTEMS MARKET BY GEOGRAPHY

7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row

Chapter: 8 COMPANY PROFILES

8.1 Medtronic Inc.

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments

8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration

8.1.5 SWOT Analysis & Strategic Conclusions

8.2 Dexcom Inc.

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments

8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition

8.2.5 SWOT Analysis & Strategic Conclusions

8.3 Novo Nordisk

8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions

8.4 Spring Health Solution Ltd

8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments

8.4.3.1 Principal Strategies

8.4.4 SWOT Analysis & Strategic Conclusions

8.5 Roche

8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions

8.6 Animas Corporation

8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments

8.6.3.1 Principal Strategies

8.6.4 SWOT Analysis & Strategic Conclusions

8.7 Ypsomed AG

8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments

8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements

8.7.4 SWOT Analysis & Strategic Conclusions

8.8 Insulet Corporation

8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments

8.8.3.1 Principal Strategies

8.8.4 SWOT Analysis & Strategic Conclusions

 

LIST OF TABLES

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
TABLE 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
TABLE 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
TABLE 12 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
TABLE 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
TABLE 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
TABLE 19 MEDTRONIC BUSINESS SNAPSHOT
TABLE 20 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 21 NOVA NORDISK BUSINESS SNAPSHOT
TABLE 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
TABLE 23 ROCHE BUSINESS SNAPSHOT
TABLE 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 25 YPSOMED AG BUSINESS SNAPSHOT
TABLE 26 INSULET CORPORATION BUSINESS SNAPSHOT


LIST OF FIGURES

FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
FIG. 3 TREATMENT OF DIABETES, 2011
FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
FIG. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
FIG. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
FIG. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
FIG. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
FIG. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
FIG. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
FIG. 11 GLOBAL MARKET PLAYERS POSITIONING
FIG. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
FIG. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
FIG. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
FIG. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES
FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
FIG. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
FIG. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
FIG. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
FIG. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
FIG. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)

The global continuous glucose monitors (CGM) market is at its emerging state. The market has witnessed launch of various continuous glucose monitoring devices in last 7 to 8 years with continuous improvement in technology. Furthermore, innovations are expected to translate the entire market scenario in the coming five to seven years. The open loop continuous glucose monitoring can now be regarded as closed with the introduction of artificial pancreas named MiniMed 530G with Enlite by Medtronic in September 2013. Launch of this product has taken diabetic care management to a next level. The market is overcoming several challenges towards the commercialization of closed loop CGMs due to significant focus on technological innovation. This is expected to take the concept of CGMs to a next level from research to large level adoption. Major factors driving the market growth are convenience offered by CGM over conventional glucose monitoring devices, earlier detection of the Hypo and Hyperglycemic events, global rise in incidences of diabetes cases, and awareness among global population.

This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Hydrogel is a water-insoluble polymer chain network that can retain high water content within its structure (about 90% water in the gel base). Hydrogels are used in hygiene products such as baby diapers, sanitary pads, adult incontinence pads, and soft contact lenses. In addition, they are increasingly used in wound care dressings for cleansing and debriding necrotic tissues in wounds. They are also used during the treatment of partial or thick wounds, necrotic wounds, burns, and autolytic debridement.
    May 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The global IVF market was valued at $9.3 billion in 2012 and is expected to grow up to $21.6 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the IVF market, as the chances of conceiving lowers with age. The pregnancy success rate with IVF technique is higher in the age group of 35-39.Globally, the number of couples with infertility issues was found to be 48.5 million in 2010.
    Jan 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Surgical robotic systems are a combination of equipment, accessories, software, and services that help to perform several minimally invasive surgeries including gynecological, cardiac, neurological, orthopedic, and others.
    Jan 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Micromanipulator is a device, which is used to perform intricate procedures or manipulate minute specimens using a microscope. These devices are generally used along with a microscope equipped with an input joystick, a mechanism to reduce the area of movement. They cater to a wide variety of applications ranging from cell micromanipulation to industrial micromanipulation, embracing semiconductors and electronic industries, among others.
    Nov 2015 | Price: $3516(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    According to WHO (World Health Organization), an estimated 276,000 babies die within 4 weeks of birth every year, from congenital anomalies. In many countries, congenital anomalies are important causes of childhood death, chronic illness and disability. The rising incidences of congenital anomalies, increasing adoption rate, rising awareness raised the need for pediatric interventional cardiology devices.
    Aug 2016 | View Details >>
  • ...
    Nephrology and urology devices are medical devices that are used for the treatment of urinary system and kidney diseases such as chronic kidney diseases (CKD), urinary incontinence and pelvic organ prolapse, kidney stone, benign prostatic hyperplasia (BPH) and end stage renal disease (ESRD). According to WHO, more than 190 million patients suffer from chronic renal failure and undergo renal dialysis and over 220 million males suffer from diseases associated with prostate glands such as swelling that results in blockage of the flow of urine through the body. This rising incidences of kidney and urology diseases has shifted the inclination of physicians towards use of highly advanced nephrology and urology devices that significantly reduce treatment and recovery time.
    Aug 2016 | View Details >>
  • ...
    Cardiovascular diseases (CVD) are one of the foremost public health challenge across the globe. According to World Organization (WHO) estimate, about 17.5 million people died from cardiovascular diseases in 2012, accounting for 31% of all global deaths. Around one third of CVD deaths take place in the low and middle income countries. By the year 2030, more than 23 million people are likely to die annually from cardiovascular diseases.
    Aug 2016 | View Details >>
  • ...
    Ultrasound is a medical imaging modality that uses high-frequency sound waves to visualize the internal organs of the body. It is equipped with a probe that transmits the high-frequency ultrasonic sound waves into the body of the patient. These sound waves are then reflected back by the body organs into the probe and are transmitted to a display machine that generates the image with the help of echoes. An ultrasound system is used to visualize liver, kidneys, blood vessels, heart, human fetus, and other organs.
    Aug 2016 | View Details >>